Embark Early Education Ltd
🇩🇪Germany
- Country
- 🇩🇪Germany
- Ownership
- Public
- Established
- 1993-01-01
- Employees
- 5.1K
- Market Cap
- $1.3B
- Website
- http://evotec.com
- Introduction
Evotec SE engages in the discovery and development of new drugs for pharmaceutical and biotechnology companies. It operates through the following segments: EVT Execute and EVT Innovate. The EVT Execute segment provides stand-alone or integrated drug discovery solutions for collaborators targets and programmers on a typical fee-for-service basis or through a variety of commercial structures, which may include performance-based components, such as milestones and royalties. The EVT Innovate develops drug discovery projects, assets and platforms, both internally or through academic collaborations. The company was founded by Manfred Eigen, Karsten Henco, Ulrich Aldag, Freimut Leidenberger, Heinrich Maria Schulte, Rudolf Rigler, and Charles Weissmann on December 8, 1993 and is headquartered in Hamburg, Germany.
Seer Showcases Scalable Proteomic Advancements Impacting Alzheimer's, Population
Seer, Inc. presents advancements at HUPO 2024, showcasing the Proteograph™ Product Suite's capabilities in Alzheimer’s research, population-scale plasma analysis, immune dynamics in xenotransplantation, and more. The platform enables deep, unbiased proteomic data generation at unprecedented speed and scale, driving proteomic science adoption and expansion.
Seer Showcases Scalable Proteomic Advancements Impacting
Seer, Inc. presents advancements at HUPO 2024, showcasing the Proteograph™ Product Suite's power in proteomic research, including studies on Alzheimer’s Disease, population health, whole blood microsampling, and xenotransplantation. External collaborators also highlight Seer’s platform versatility.
UK In Vivo CRO Market Size & Outlook, 2023-2030
UK in vivo CRO market generated USD 291.5 million in 2023, projected to reach USD 495.4 million by 2030, growing at a CAGR of 7.9%. Small molecule was the largest segment in 2023, while Large Molecule is the fastest growing. The UK market is significant in Europe, driven by preclinical services development and the 3Rs principles, aiming to reduce animal usage in research.
A New Barometer For Clinical Outsourcing Performance
Andrew Schafer created the Schafer Clinical Development Index (SCDI) to track the performance of the clinical development industry, focusing on outsourcing. The SCDI, composed of 14 public companies, is down 20% YTD, contrasting with the DJIA and NASDAQ gains. Schafer plans to expand analysis to include CRO backlog tracking and continue 'Pharma Feud' posts on LinkedIn.
BioDuro-Sundia Bolsters Drug Discovery Services with New Center in Shanghai
BioDuro-Sundia launched a state-of-the-art Compound Management Center in Shanghai to enhance drug discovery capabilities, offering secure storage, real-time inventory tracking, and rapid sample access. The center aims to expedite R&D, reduce costs, and accelerate therapy candidate discoveries.
Five tech breakthroughs bringing us closer to beating cancer
Recent acquisitions of cancer drug developers RayzeBio and Fusion Pharmaceuticals highlight radiotherapy's resurgence. Oncology sees advancements in genetics, immunology, AI, and personalized treatments. Funding remains robust, with potential for highest corporate rounds since 2021. Combination therapies and AI are crucial, with cancer vaccines and precision treatments offering hope. Despite challenges, progress in treating specific cancers has improved patient outcomes.
Evotec opens first European biologics facility in France
The article discusses the importance of SSR (Server-Side Rendering) in web development, highlighting its role in improving performance and user experience.
Combating Diseases with Limited Investment Incentives: Q&A with Dr. Claire Wagner
Dr. Claire Wagner, head of corporate strategy and market access at the Bill & Melinda Gates Medical Research Institute, focuses on developing medications for diseases primarily impacting Low and Middle-Income Countries (LMICs), where commercial incentives are limited. The Gates MRI prioritizes global health equity, targeting diseases like tuberculosis, malaria, and diarrheal diseases. Wagner emphasizes the importance of policy alignment, innovative financing, and strong partnerships to ensure products reach those in need, drawing on her experience in Rwanda and collaborations with global health organizations. The institute is currently developing vaccines and therapeutics, including a TB vaccine candidate and a probiotic supplement for malnourished children.
Kazia Therapeutics Announces Presentation of Promising Phase I Data Evaluating ...
Kazia Therapeutics reported a 67% partial response rate with 45mg paxalisib and radiotherapy in a Phase I study for solid tumor brain metastases with PI3K pathway mutations, presented at ASTRO 2024. Over two-thirds of patients at maximum tolerated dose achieved intracranial response, suggesting paxalisib's potential in overcoming tumor radioresistance.
Recursion gains FDA clearance for Phase 1/2 cancer drug trial
Recursion received FDA clearance for a Phase 1/2 trial of REC-1245, targeting solid tumors and lymphoma, set to start in Q4 2024. The drug, developed using AI, targets RBM39, potentially addressing a significant unmet need. Recursion's platform combines experimental and computational approaches for drug discovery. The company, listed on NASDAQ: RXRX, is based in Salt Lake City and part of the Utah life sciences collective, BioHive.
© Copyright 2025. All Rights Reserved by MedPath